Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,277 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Reactive Vasodilation Predicts Mortality in Primary Systemic Light-Chain Amyloidosis.
Stamatelopoulos K, Georgiopoulos G, Athanasouli F, Nikolaou PE, Lykka M, Roussou M, Gavriatopoulou M, Laina A, Trakada G, Charakida M, Delialis D, Petropoulos I, Pamboukas C, Manios E, Karakitsou M, Papamichael C, Gatsiou A, Lambrinoudaki I, Terpos E, Stellos K, Andreadou I, Dimopoulos MA, Kastritis E. Stamatelopoulos K, et al. Among authors: dimopoulos ma. Circ Res. 2019 Sep 27;125(8):744-758. doi: 10.1161/CIRCRESAHA.119.314862. Epub 2019 Aug 12. Circ Res. 2019. PMID: 31401949 Free PMC article.
Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.
Kastritis E, Roussou M, Gavriatopoulou M, Migkou M, Kalapanida D, Pamboucas C, Kaldara E, Ntalianis A, Psimenou E, Toumanidis ST, Tasidou A, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: dimopoulos ma. Am J Hematol. 2015 Apr;90(4):E60-5. doi: 10.1002/ajh.23936. Epub 2015 Mar 9. Am J Hematol. 2015. PMID: 25580702 Free article.
Recent advances in the management of AL Amyloidosis.
Kastritis E, Dimopoulos MA. Kastritis E, et al. Among authors: dimopoulos ma. Br J Haematol. 2016 Jan;172(2):170-86. doi: 10.1111/bjh.13805. Epub 2015 Oct 22. Br J Haematol. 2016. PMID: 26491974 Free article. Review.
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone.
Kastritis E, Dialoupi I, Gavriatopoulou M, Roussou M, Kanellias N, Fotiou D, Ntanasis-Stathopoulos I, Papadopoulou E, Ziogas DC, Stamatelopoulos K, Manios E, Ntalianis A, Eleutherakis-Papaiakovou E, Papanikolaou A, Migkou M, Papanota AM, Gakiopoulou H, Psimenou E, Tselegkidi MI, Tsitsilonis O, Kostopoulos I, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: dimopoulos ma. Blood Adv. 2019 Oct 22;3(20):3002-3009. doi: 10.1182/bloodadvances.2019000147. Blood Adv. 2019. PMID: 31648323 Free PMC article.
Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis.
Kastritis E, Fotiou D, Theodorakakou F, Dialoupi I, Migkou M, Roussou M, Karatrasoglou EA, Tselegkidi MI, Ntalianis A, Kanellias N, Eleutherakis-Papaiakovou E, Ntanasis-Stathopoulos I, Gakiopoulou C, Papanikolaou A, Papathoma A, Spyropoulou-Vlachou M, Psimenou E, Stamatelopoulos K, Gavriatopoulou M, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: dimopoulos ma. Amyloid. 2021 Mar;28(1):3-11. doi: 10.1080/13506129.2020.1798224. Epub 2020 Jul 27. Amyloid. 2021. PMID: 32713209
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone.
Kastritis E, Anagnostopoulos A, Roussou M, Toumanidis S, Pamboukas C, Migkou M, Tassidou A, Xilouri I, Delibasi S, Psimenou E, Mellou S, Terpos E, Nanas J, Dimopoulos MA. Kastritis E, et al. Among authors: dimopoulos ma. Haematologica. 2007 Oct;92(10):1351-8. doi: 10.3324/haematol.11325. Haematologica. 2007. PMID: 18024372 Free article. Clinical Trial.
Bortezomib for AL amyloidosis: moving forward.
Dimopoulos MA, Kastritis E. Dimopoulos MA, et al. Blood. 2011 Jul 28;118(4):827-8. doi: 10.1182/blood-2011-05-355115. Blood. 2011. PMID: 21799093 Free article. No abstract available.
A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis.
Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Pamboukas C, Boletis I, Marinaki S, Apostolou T, Nikitas N, Gkortzolidis G, Michalis E, Delimpasi S, Dimopoulos MA. Kastritis E, et al. Among authors: dimopoulos ma. Blood. 2012 Jun 7;119(23):5384-90. doi: 10.1182/blood-2011-12-396903. Epub 2012 Apr 18. Blood. 2012. PMID: 22517904 Free article. Clinical Trial.
Less strength and more fractures for MGUS bones.
Terpos E, Dimopoulos MA. Terpos E, et al. Among authors: dimopoulos ma. Blood. 2014 Jan 30;123(5):603-4. doi: 10.1182/blood-2013-11-539973. Blood. 2014. PMID: 24482495 Free article.
1,277 results